News >

Trastuzumab Biosimilar Ogivri Launches in United States

Gina Columbus
Published: Tuesday, Dec 03, 2019

Hope Rugo, MD

Hope Rugo, MD

The trastuzumab (Herceptin) biosimilar Ogivri (MYL-1401O; trastuzumab-dkst) has been launched in the United States for all indications of the reference product, including the treatment of patients with HER2-overexpressing breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication